ClinicalTrials.gg
CompletedNCT03703375Updated Jun 12, 2026Results posted

Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma

A Phase 3 interventional study of Azacitidine and Romidepsin in Lymphoma, T-Cell, sponsored by Celgene. Completed at 12 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-12.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
93
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study is a multicentric, open-label, randomized phase 3 trial. The study will be conducted in select countries in Europe and South Korea sponsored by LYSARC and in Japan sponsored by Celgene. There will be a combined enrollment target of 86 randomized patients, with approximately 14 randomized patients from Japan.

The enrollment to the randomized study will start at European sites in parallel to a safety run-in part in Japan. A safety run-in will be conducted to confirm the tolerability of oral azacitidine at doses of 100 mg and 200 mg QD in Asian patients. Once oral azacitidine at 200 mg QD is confirmed as tolerable, Asian patients from Japan and South Korea will start to be randomized into the main study. Additional patients (non-randomized) are anticipated to enroll to the safety run-in.

02

Conditions studied

  • Lymphoma, T-Cell

Keywords

  • CC-486
  • Azacitidine
  • Angioimmunoblastic
  • T Cell Lymphoma
  • Lymphoma
03

In context

Lymphoma, T-Cell

310 studies on the registry are indexed under Lymphoma, T-Cell; 77 are open to participants now.

This study's enrollment of 93 is above the median of 37 across 270 interventional studies indexed under Lymphoma, T-Cell.

Browse Lymphoma, T-Cell studies →

Lead sponsor

Celgene is the lead sponsor of 428 studies on the registry; 12 are open to participants now.

Of its 104 completed or terminated interventional studies of FDA-regulated products, 30 (29%) have results posted.

First submitted before Celgene became part of Bristol-Myers Squibb.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient is ≥ 18 years of age at the time of signing the form (ICF).
  2. Patient must understand and voluntarily sign an ICF prior to any study-specific assessments/procedures being conducted.
  3. Patient is willing and able to adhere to the study visit schedule and other protocol requirements
  4. Patient had local diagnosed peripheral T cell lymphoma (PTCL) with T-follicular helper (TFH) phenotype according to the criteria of the latest WHO classification based on a surgical lymph node or needle core biopsy including any one of

    • Angioimmunoblastic T cell lymphoma (AITL)
    • Follicular T cell lymphoma
    • Nodal peripheral T-cell lymphoma with TFH phenotype There should be a documented expression of minimum two TFH markers among this panel of markers: CD10, CXCL13, PD1, ICOS and BCL6 by the tumoral cells by immunohistochemistry. Biopsy at relapse or progression is not mandatory, but highly encouraged on a surgical or needle core biopsy, and diagnostic tissue should be available for central pathology review and for ancillary molecular studies.

    Local pathology report should be reviewed by the sponsor's medical monitor prior to enrollment.

  5. performance status 0 to 3
  6. (after partial or complete response) or refractory AITL after at least one (there is no mandatory resting period after the previous treatment as long as the biochemistry and hematology labs meet the inclusion criteria as below.)
  7. Meet the following lab criteria:

    • ≥ 1,5 x 109/L (≥ 1 x 109/L if BM involvement by lymphoma)
    • ≥ 75 x 109/L (≥ 50 x 109/L if BM involvement by lymphoma)
    • ≥ 8 g/dL.
  8. Anticipated at least 3 months
  9. At least one on CT that is greater than 1.5 cm in the longest diameter for nodal lesions and greater than 1.0 cm in the longest diameter for extranodal lesions. The lesion must be measurable in two perpendicular dimensions. Patients with only cutaneous disease will be excluded.
  10. Female patient of (FCBP) may participate, providing she meets the following conditions:

    Have two negative pregnancy tests as verified by the investigator prior to starting study treatment: serum pregnancy test at Screening and negative serum or urine pregnancy test (investigator's discretion) within 72 hours prior to starting treatment with study treatment (Cycle 1 Day 1). She must agree to ongoing pregnancy testing during the study (before beginning each subsequent cycle of treatment), and 28 days after the last study drug administration. This applies even if the patient practices complete abstinence from heterosexual contact.

    Agrees to practice true abstinence (which must be reviewed monthly and source documented) or agrees to the use of highly effective methods of from 28 days prior to starting study treatment, and must agree to continue using such precautions during study treatment (including dose interruptions) and for up to 6 months after the last study drug administration. True abstinence is acceptable when this is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (eg, calendar, ovulation, symptomthermal, post ovulation methods) and withdrawal are not acceptable methods of contraception. Cessation of contraception after this point should be discussed with a responsible physician.

    Agrees to abstain from breastfeeding during study participation and for at least 6 months after the last study drug administration.

    A female of childbearing potential (FCBP) is a female who: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy or 3) has not been naturally (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time during the preceding 24 consecutive months).

  11. Male patient must either practice true abstinence from heterosexual contact (which must be reviewed on a monthly basis and source documented) or agrees to avoid fathering a child, to use highly effective methods of contraception, male condom plus spermicide during sexual contact with a pregnant female or a female of childbearing potential (even if he has undergone a successful vasectomy), from starting dose of IP (cycle 1 Day 1), including dose interruptions through 6 months after receipt of the last study drug administration.

    Furthermore, male patient must agree to not give semen or sperm during study drug therapy and for a period of 1 year after end of study drug therapy.

  12. For EU countries, patient covered by a social security system

Exclusion criteria

Exclusion Criteria:

  1. Clinical evidence of central nervous system(CNS) involvement by lymphoma. Patients with suspicion of CNS involvement must undergo neurologic evaluation and CT/MRI of head and lumbar puncture to exclude CNS disease.
  2. Any significant medical conditions, laboratory abnormality or psychiatric illness likely to interfere with participation in this clinical study (according to the investigator's decision)
  3. Uncontrolled systemic fungal, bacterial, or viral infection (defined as ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics, antiviral therapy, and/or other treatment)
  4. Known (HIV) or Virus (HCV) infection, or evidence of active Virus (HBV) infection defined as:

    • HBs Ag positive
    • HBs Ag negative, anti-HBs antibody positive and/or anti-HBc antibody positive with detectable viral DNA
  5. Impaired renal function (calculated or Creatinine Clearance \< 30 ml/min) or impaired liver function tests (Serum total level > 2.0 mg/dl [34 μmol/L] (except in case of Gilbert's Syndrome, or documented liver or pancreatic involvement by lymphoma), Serum transaminases ( or ALT) > 3 upper normal limits) unless they are related to the lymphoma.
  6. Active other than the one treated in this research. Prior history of malignancies, other than low risk MDS or CMML (with less than 5% blasts in bone marrow), unless the patient has been free of the disease for ≥ 3 years. However, patients with the following history/concurrent conditions are allowed:

    1. Basal or squamous cell carcinoma of the skin
    2. Carcinoma in situ of the cervix
    3. Carcinoma in situ of the breast
    4. Incidental histologic finding of prostate cancer (T1a or T1b) using the tumor, nodes, [TNM] clinical staging system
  7. Treatment with any drug within 5 half-lives before planned first cycle of study treatment and during the study. Ongoing medically significant adverse events from previous treatment, regardless of the time period.
  8. Prior exposure to azacitidine and/ or any other demethylating agent (eg, decitabine)
  9. Prior exposure to planned study treatment investigator's choice therapy (eg, prior exposure to gemcitabine is an exclusion if gemcitabine is the investigator's choice therapy prior to randomization)
  10. Concurrent use of unless the patient is on a stable or decreasing dose for ≥ 1 week prior to form signature
  11. Knowing or suspected to active substance or to any of the .
  12. Pregnant, planning to become pregnant, or lactating woman
  13. Candidate for hematopoietic stem cell transplantation
  14. History of active inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis), celiac disease (ie, sprue), prior gastrectomy or upper bowel removal, or any other gastrointestinal disorder or defect that would interfere with the absorption, distribution, metabolism or excretion of the oral azacitidine and/or predispose the patient to an increased risk of gastrointestinal toxicity per investigator's decision. Any condition causing inability to swallow tablets.
  15. Significant active cardiac disease within the previous 6 months, including:

    • (NYHA) class IV congestive heart failure
    • Unstable angina or angina requiring surgical or medical intervention; and/or
    • Myocardial infarction
  16. Person deprived of his/her liberty by a judicial or administrative decision
  17. Adult person under legal protection
Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
93 participants (actual)

Study arms

  • Experimental
    Administration of Oral Azacitidine (CC-486)

    Oral azacytidine 300 mg during 14 first days of 28-days cycle for European (EU) patients, Oral azacytidine 200 mg during 14 first days of 28-days cycle for Asian patients (Treatment until progression, patient decision or toxicity)

    Drug: Azacitidine

  • Active comparator
    Investigator's choice therapy - Romidepsin

    Romidepsin 14mg/m2 on days 1, 8 and 15 of a 28-days cycle (Treatment until progression, patient decision or toxicity)

    Drug: Romidepsin

  • Active comparator
    Investigator's choice therapy - Gemcitabine

    Gemcitabine 1000mg/m2 on days 1, 8 and 15 of a 28-days cycle (during 6 cycles)

    Drug: Gemcitabine

Interventions

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS) Based on Local Assessment

    PFS is defined as the time from randomization into the study to the first observation of documented disease progression (local assessment using Lugano Response Criteria 2014) or death due to any cause, whichever occurs first. If a participant has not progressed or died, PFS will be censored at the time of last visit with adequate assessment. C2 censoring rules were used per US FDA guidance 2015. Progression will be determined as per Response criteria for lymphoma: Lugano classification.

    Time frame: From randomization up to documented disease progression or death, whichever occurs first (up to approximately 15 months)

Secondary outcomes

  1. Overall Survival (OS)

    Overall survival is defined as the time from the date of randomization to the date of death from any cause. OS was censored at the last date that the participant was known to be alive.

    Time frame: From randomization up to the date of death or date last known alive (up to approximately 27 months)

  2. Progression Free Survival (PFS) Based on IRC Assessment

    PFS based on Independant Review Committee (IRC) is defined as the time from randomization into the study to the first observation of documented disease progression (reviewed assessment by IRC using Lugano Response Criteria 2014) or death due to any cause. If a patient has not progressed or died, PFS will be censored at the time of last visit with adequate assessment per FDA's guidance 2015 Table C2. Progression will be determined as per Response criteria for lymphoma: Lugano classification.

    Time frame: From randomization up to documented disease progression or death, whichever occurs first (up to approximately 37 months)

  3. Overall Response Rates (ORR)

    Overall response rates are the percentage of complete response (CR) and partial response (PR) per local assessment. Assessment of response will be based on Lugano Response Criteria 2014 for the radiologic response (CT based), the metabolic response (PET-CT based) and the best response between radiologic and metabolic response. Measurements occurred after Cycle 3, after Cycle 6, and at permanent treatment discontinuation. PR is defined as Score 4 or 5 with reduced uptake compared with baseline and residual mass(es) of any size and ≥ 50% decrease in SPD of up to 6 target measurable nodes and extranodal sites. CR is defined as target nodes/nodal masses regressed to ≤ 1.5 cm in LDi, no extralymphatic sites of disease, and Score 1, 2, or 3 with or without a residual mass on the 5 Point Scale. The Lugano 5-point scale is 1, no uptake above background; 2, uptake mediastinum; 3, uptake mediastinum but liver; 4, uptake moderately liver; 5, uptake markedly higher than liver and/or new lesions.

    Time frame: Response rate will be measured after Cycle 3, after Cycle 6 (up to approximately 5.5 months)

  4. Complete Response Rate (CRR)

    Complete response rate is the percentage of CR (complete metabolic response or CT-based CR) per local assessment before receiving any subsequent anti-lymphoma therapy. Assessment will be based on Lugano Response Criteria 2014 for the radiologic response (CT based), the metabolic response (PET-CT based) and best response between radiologic and metabolic response. Measurements occurred after Cycle 3, Cycle 6, and treatment discontinuation. PR is defined as Score 4 or 5 with reduced uptake compared with baseline and residual mass(es) of any size and ≥ 50% decrease in SPD of up to 6 target measurable nodes and extranodal sites. CR is defined as target nodes/nodal masses regressed to ≤ 1.5 cm in LDi, no extralymphatic sites of disease, and Score 1, 2, or 3 with or without a residual mass. The Lugano 5-point scale is 1, no uptake above background; 2, uptake mediastinum; 3, uptake mediastinum but liver; 4, uptake moderately liver; 5, uptake markedly higher than liver and/or new lesions.

    Time frame: Response rate will be measured after Cycle 3, after Cycle 6 (up to approximately 5.5 months)

  5. Duration of Response (DOR)

    Duration of response is defined as the time from attainment of complete response (CR) or partial response (PR) per local assessment to the date of first documented disease progression, relapse (local assessment) or death from any cause. Participants alive and free of progression will be censored at their last visit with adequate assessment.CR: complete metabolic response or computed tomography (CT)-based CR; PR: partial metabolic response or CT-based PR before subsequent anti-lymphoma therapy.

    Time frame: From randomization to the date of first documented disease progression, relapse (local assessment) or death from any cause (up to approximately 27 months)

  6. Time to Response (TTR)

    Time to response is defined as the time from randomization to the date of attainment of complete response (CR) or partial response (PR) per local assessment until end of treatment. If a participant is not responder, time to response will be censored at the time of last visit with adequate assessment. CR: complete metabolic response or computed tomography (CT)-based CR; PR: partial metabolic response or CT-based PR before subsequent anti-lymphoma therapy.

    Time frame: From randomization to the date of attainment of complete response (CR) or partial response (PR) until end of treatment (up to approximately 37 months)

  7. Progression Free Survival 2 (PFS2) on Local Assessment

    PFS2 based on local assessment is defined as the time from randomization to objective tumor progression on next-line treatment or death from any cause. Participants without next-line therapy who did not die and participants who did not relapse or not die after next-line therapy will be censored at the last adequate tumor assessment date.

    Time frame: From randomization to objective tumor progression on next-line treatment or death from any cause (up to approximately 27 months)

  8. Mean Change in Minimal Important Differences (MIDs) of the EORTC QLQ-C30 Health-related Quality-of-Life Domain Scores

    The minimal important difference (MID) is the size of difference in Quality-of-Life score that is considered relevant (i.e. warranting a change in treatment or examinations). The European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQC30) subscale values are the lower threshold for MID over time, based on within-group mean change. QLQ-C30 has 5 functional scales (physical, role, emotional, cognitive, social), 3 symptom scales (fatigue, nausea/vomiting, pain), a global health status / quality of life (QoL) scale, and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties). Each scale was scored on a range from 0 to 100. Higher scores represent a higher response level. Note that a high score for global health status or for a functional scale represents a high or healthy level of functioning, but a high score for a symptom scale/item represents a high level of symptomatology/problems.

    Time frame: At baseline and on Day 1 of each cycle up to treatment discontinuation (up to approximately 27 months)

07

Results

Posted Jul 8, 2024

Participant flow

Pre-Randomization (Safety Run-In)
Participant flow — Pre-Randomization (Safety Run-In)
MilestoneOral AzacitidineInvestigators Choice Therapy - RomidepsinInvestigators Choice Therapy - BendamustineInvestigators Choice Therapy - Gemcitabine
Started7000
Completed7000
Not completed0000
Randomization Period
Participant flow — Randomization Period
MilestoneOral AzacitidineInvestigators Choice Therapy - RomidepsinInvestigators Choice Therapy - BendamustineInvestigators Choice Therapy - Gemcitabine
Started4941624
Safety run-in7000
Completed4241623
Not completed7001
Withdrew: Withdrawal by subject0001
Withdrew: Completed safety run-in treatment7000
Treatment Period
Participant flow — Treatment Period
MilestoneOral AzacitidineInvestigators Choice Therapy - RomidepsinInvestigators Choice Therapy - BendamustineInvestigators Choice Therapy - Gemcitabine
Started4241623
Completed0045
Not completed4241218
Withdrew: Other reasons0103
Withdrew: Consent withdrawal0001
Withdrew: Death1012
Withdrew: Toxicity of study treatment2041
Withdrew: Progression321711
Withdrew: Completed treatment7200

Outcome measures

PrimaryProgression Free Survival (PFS) Based on Local Assessment

PFS is defined as the time from randomization into the study to the first observation of documented disease progression (local assessment using Lugano Response Criteria 2014) or death due to any cause, whichever occurs first. If a participant has not progressed or died, PFS will be censored at the time of last visit with adequate assessment. C2 censoring rules were used per US FDA guidance 2015. Progression will be determined as per Response criteria for lymphoma: Lugano classification.

Time frame:
From randomization up to documented disease progression or death, whichever occurs first (up to approximately 15 months)
Reported as:
Median · Months
Progression Free Survival (PFS) Based on Local Assessment
MonthsOral AzacitidineInvestigators Choice Therapy Combined (Romidepsin, Bendamustine, Gemcitabine)
Progression Free Survival (PFS) Based on Local Assessment5.6 (2.66 to 7.26)2.8 (1.87 to 4.83)
Statistical analysis
  • Oral Azacitidine vs Investigators Choice Therapy Combined (Romidepsin, Bendamustine, Gemcitabine) · Stratified Cox · p = 0.0541 · Hazard ratio (hr): 0.67 · 95% CI 0.41 to 1.09Stratified Cox proportional hazards model
SecondaryOverall Survival (OS)

Overall survival is defined as the time from the date of randomization to the date of death from any cause. OS was censored at the last date that the participant was known to be alive.

Time frame:
From randomization up to the date of death or date last known alive (up to approximately 27 months)
Reported as:
Median · Months
Overall Survival (OS)
MonthsOral AzacitidineInvestigators Choice Therapy Combined (Romidepsin, Bendamustine, Gemcitabine)
Overall Survival (OS)18.4 (12.88 to 31.47)10.3 (4.24 to 13.50)
Statistical analysis
  • Oral Azacitidine vs Investigators Choice Therapy Combined (Romidepsin, Bendamustine, Gemcitabine) · Efron · p = 0.0166 · Hazard ratio (hr): 0.56 · 95% CI 0.32 to 0.96Stratified Cox proportional hazards model
SecondaryProgression Free Survival (PFS) Based on IRC Assessment

PFS based on Independant Review Committee (IRC) is defined as the time from randomization into the study to the first observation of documented disease progression (reviewed assessment by IRC using Lugano Response Criteria 2014) or death due to any cause. If a patient has not progressed or died, PFS will be censored at the time of last visit with adequate assessment per FDA's guidance 2015 Table C2. Progression will be determined as per Response criteria for lymphoma: Lugano classification.

Time frame:
From randomization up to documented disease progression or death, whichever occurs first (up to approximately 37 months)
Reported as:
Median · Months
Progression Free Survival (PFS) Based on IRC Assessment
MonthsOral AzacitidineInvestigators Choice Therapy Combined (Romidepsin, Bendamustine, Gemcitabine)
Progression Free Survival (PFS) Based on IRC Assessment4.2 (2.66 to 5.88)3.2 (2.10 to 4.83)
Statistical analysis
  • Oral Azacitidine vs Investigators Choice Therapy Combined (Romidepsin, Bendamustine, Gemcitabine) · Stratified Cox · p = 0.2139 · Hazard ratio (hr): 0.82 · 95% CI 0.51 to 1.33Stratified Cox proportional hazards model
SecondaryOverall Response Rates (ORR)

Overall response rates are the percentage of complete response (CR) and partial response (PR) per local assessment. Assessment of response will be based on Lugano Response Criteria 2014 for the radiologic response (CT based), the metabolic response (PET-CT based) and the best response between radiologic and metabolic response. Measurements occurred after Cycle 3, after Cycle 6, and at permanent treatment discontinuation. PR is defined as Score 4 or 5 with reduced uptake compared with baseline and residual mass(es) of any size and ≥ 50% decrease in SPD of up to 6 target measurable nodes and extranodal sites. CR is defined as target nodes/nodal masses regressed to ≤ 1.5 cm in LDi, no extralymphatic sites of disease, and Score 1, 2, or 3 with or without a residual mass on the 5 Point Scale. The Lugano 5-point scale is 1, no uptake above background; 2, uptake mediastinum; 3, uptake mediastinum but liver; 4, uptake moderately liver; 5, uptake markedly higher than liver and/or new lesions.

Time frame:
Response rate will be measured after Cycle 3, after Cycle 6 (up to approximately 5.5 months)
Reported as:
Number · Percentage of participants
Overall Response Rates (ORR)
Percentage of participantsOral AzacitidineInvestigators Choice Therapy Combined (Romidepsin, Bendamustine, Gemcitabine)
Cycle 333.3 (19.6 to 49.5)43.2 (28.3 to 59.0)
Cycle 631.0 (17.6 to 47.1)22.7 (11.5 to 37.8)
SecondaryComplete Response Rate (CRR)

Complete response rate is the percentage of CR (complete metabolic response or CT-based CR) per local assessment before receiving any subsequent anti-lymphoma therapy. Assessment will be based on Lugano Response Criteria 2014 for the radiologic response (CT based), the metabolic response (PET-CT based) and best response between radiologic and metabolic response. Measurements occurred after Cycle 3, Cycle 6, and treatment discontinuation. PR is defined as Score 4 or 5 with reduced uptake compared with baseline and residual mass(es) of any size and ≥ 50% decrease in SPD of up to 6 target measurable nodes and extranodal sites. CR is defined as target nodes/nodal masses regressed to ≤ 1.5 cm in LDi, no extralymphatic sites of disease, and Score 1, 2, or 3 with or without a residual mass. The Lugano 5-point scale is 1, no uptake above background; 2, uptake mediastinum; 3, uptake mediastinum but liver; 4, uptake moderately liver; 5, uptake markedly higher than liver and/or new lesions.

Time frame:
Response rate will be measured after Cycle 3, after Cycle 6 (up to approximately 5.5 months)
Reported as:
Number · Percentage of participants
Complete Response Rate (CRR)
Percentage of participantsOral AzacitidineInvestigators Choice Therapy Combined (Romidepsin, Bendamustine, Gemcitabine)
Cycle 311.9 (4.0 to 25.6)22.7 (11.5 to 37.8)
Cycle 611.9 (4.0 to 25.6)15.9 (6.6 to 30.1)
SecondaryDuration of Response (DOR)

Duration of response is defined as the time from attainment of complete response (CR) or partial response (PR) per local assessment to the date of first documented disease progression, relapse (local assessment) or death from any cause. Participants alive and free of progression will be censored at their last visit with adequate assessment.CR: complete metabolic response or computed tomography (CT)-based CR; PR: partial metabolic response or CT-based PR before subsequent anti-lymphoma therapy.

Time frame:
From randomization to the date of first documented disease progression, relapse (local assessment) or death from any cause (up to approximately 27 months)
Reported as:
Number · Percentage of participants
Duration of Response (DOR)
Percentage of participantsOral AzacitidineInvestigators Choice Therapy Combined (Romidepsin, Bendamustine, Gemcitabine)
Duration of Response (DOR)10.4 (2.56 to NA)3.4 (2.00 to NA)
SecondaryTime to Response (TTR)

Time to response is defined as the time from randomization to the date of attainment of complete response (CR) or partial response (PR) per local assessment until end of treatment. If a participant is not responder, time to response will be censored at the time of last visit with adequate assessment. CR: complete metabolic response or computed tomography (CT)-based CR; PR: partial metabolic response or CT-based PR before subsequent anti-lymphoma therapy.

Time frame:
From randomization to the date of attainment of complete response (CR) or partial response (PR) until end of treatment (up to approximately 37 months)
Reported as:
Median · Months
Time to Response (TTR)
MonthsOral AzacitidineInvestigators Choice Therapy Combined (Romidepsin, Bendamustine, Gemcitabine)
Time to Response (TTR)3 (3 to 6)2.7 (1 to 4)
SecondaryProgression Free Survival 2 (PFS2) on Local Assessment

PFS2 based on local assessment is defined as the time from randomization to objective tumor progression on next-line treatment or death from any cause. Participants without next-line therapy who did not die and participants who did not relapse or not die after next-line therapy will be censored at the last adequate tumor assessment date.

Time frame:
From randomization to objective tumor progression on next-line treatment or death from any cause (up to approximately 27 months)
Reported as:
Median · Months
Progression Free Survival 2 (PFS2) on Local Assessment
MonthsOral AzacitidineInvestigators Choice Therapy Combined (Romidepsin, Bendamustine, Gemcitabine)
Progression Free Survival 2 (PFS2) on Local Assessment11.0 (6.44 to 18.89)6.7 (3.52 to 9.56)
SecondaryMean Change in Minimal Important Differences (MIDs) of the EORTC QLQ-C30 Health-related Quality-of-Life Domain Scores

The minimal important difference (MID) is the size of difference in Quality-of-Life score that is considered relevant (i.e. warranting a change in treatment or examinations). The European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQC30) subscale values are the lower threshold for MID over time, based on within-group mean change. QLQ-C30 has 5 functional scales (physical, role, emotional, cognitive, social), 3 symptom scales (fatigue, nausea/vomiting, pain), a global health status / quality of life (QoL) scale, and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties). Each scale was scored on a range from 0 to 100. Higher scores represent a higher response level. Note that a high score for global health status or for a functional scale represents a high or healthy level of functioning, but a high score for a symptom scale/item represents a high level of symptomatology/problems.

Time frame:
At baseline and on Day 1 of each cycle up to treatment discontinuation (up to approximately 27 months)

Results for this outcome have not been posted.

Adverse events

Collected over Participants were assessed for all-cause mortality from their enrollment to study completion, (up to approximately 37 months). SAEs and Other AEs were assessed from first dose to 28 days following last dose (up to approximately 38 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Oral Azacitidine: 200 mg6/8 (75%)2/8 (25%)7/8 (87.5%)
Oral Azacitidine: 300 mg20/34 (58.8%)9/34 (26.5%)33/34 (97.1%)
Investigators Choice Therapy - Romidepsin1/4 (25%)2/4 (50%)4/4 (100%)
Investigators Choice Therapy - Bendamustine13/16 (81.3%)8/16 (50%)16/16 (100%)
Investigators Choice Therapy - Gemcitabine: 1000 mg/m23/3 (100%)0/3 (0%)3/3 (100%)
Investigators Choice Therapy - Gemcitabine: 1200 mg/m214/21 (66.7%)9/20 (45%)19/20 (95%)
Safety Run-in Oral Azacitidine: 100 mg1/4 (25%)0/3 (0%)3/3 (100%)
Safety Run-in Oral Azacitidine: 200 mg2/3 (66.7%)1/3 (33.3%)3/3 (100%)
Most frequent serious events
Showing 10 of 44
Most frequent serious events
EventOral Azacitidine: 200 mgOral Azacitidine: 300 mgInvestigators Choice Therapy - RomidepsinInvestigators Choice Therapy - BendamustineInvestigators Choice Therapy - Gemcitabine: 1000 mg/m2Investigators Choice Therapy - Gemcitabine: 1200 mg/m2Safety Run-in Oral Azacitidine: 100 mgSafety Run-in Oral Azacitidine: 200 mg
Acute coronary syndromeCardiac disorders0/80/340/40/160/30/200/31/3
Epstein-Barr virus infection reactivationInfections and infestations1/81/341/41/160/30/200/30/3
Bladder cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/80/341/40/160/30/200/30/3
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/80/341/40/160/30/200/30/3
Febrile neutropeniaBlood and lymphatic system disorders0/80/340/43/160/30/200/30/3
Systemic candidaInfections and infestations1/80/340/40/160/30/200/30/3
Epstein-Barr virus associated lymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/80/340/40/160/30/200/30/3
Cardiac failureCardiac disorders0/81/340/40/160/32/200/30/3
CellulitisInfections and infestations0/80/340/40/160/32/200/30/3
InfectionInfections and infestations0/80/340/40/160/32/200/30/3
Most frequent other events
Showing 10 of 102
Most frequent other events
EventOral Azacitidine: 200 mgOral Azacitidine: 300 mgInvestigators Choice Therapy - RomidepsinInvestigators Choice Therapy - BendamustineInvestigators Choice Therapy - Gemcitabine: 1000 mg/m2Investigators Choice Therapy - Gemcitabine: 1200 mg/m2Safety Run-in Oral Azacitidine: 100 mgSafety Run-in Oral Azacitidine: 200 mg
LeukopeniaBlood and lymphatic system disorders0/80/340/41/163/31/201/31/3
LymphopeniaBlood and lymphatic system disorders5/815/343/414/163/315/200/32/3
ThrombocytopeniaBlood and lymphatic system disorders3/87/344/47/162/38/201/31/3
DiarrhoeaGastrointestinal disorders1/89/341/41/160/35/200/33/3
VomitingGastrointestinal disorders4/814/341/42/160/31/201/33/3
NeutropeniaBlood and lymphatic system disorders3/815/343/49/162/311/201/32/3
NauseaGastrointestinal disorders5/817/342/45/160/36/200/30/3
Febrile neutropeniaBlood and lymphatic system disorders0/80/342/40/160/30/200/30/3
StomatitisGastrointestinal disorders1/80/342/40/160/30/200/30/3
AnaemiaBlood and lymphatic system disorders3/810/341/42/161/39/200/31/3

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Oral AzacitidineInvestigators Choice Therapy - RomidepsinInvestigators Choice Therapy - BendamustineInvestigators Choice Therapy - GemcitabineTotal
Mean69.3 ± 9.2867.0 ± 7.1660.8 ± 9.9069.4 ± 10.8067.8 ± 10.11
Sex: Female, Male
Sex: Female, Male(Participants)Oral AzacitidineInvestigators Choice Therapy - RomidepsinInvestigators Choice Therapy - BendamustineInvestigators Choice Therapy - GemcitabineTotal
Female2216938
Male273101555
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Oral AzacitidineInvestigators Choice Therapy - RomidepsinInvestigators Choice Therapy - BendamustineInvestigators Choice Therapy - GemcitabineTotal
American Indian or Alaska Native00000
Asian00000
Native Hawaiian or Other Pacific Islander00000
Black or African American00000
White00000
More than one race00000
Unknown or Not Reported00000
Region of Enrollment
Region of Enrollment(Participants)Oral AzacitidineInvestigators Choice Therapy - RomidepsinInvestigators Choice Therapy - BendamustineInvestigators Choice Therapy - GemcitabineTotal
Asia1540322
Europe340162171
08

Study locations

12 sites
  • Local Institution - 41822
    Sapporo, Hokkaido 0608648, Japan
  • Local Institution - 41922
    Okayama, Okayama-ken 700-8558, Japan
  • Local Institution - 41722
    Sayama, Osaka 5898511, Japan
  • Local Institution - 41422
    Hidaka, Saitama-Pref 350-1298, Japan
  • Local Institution - 40722
    Chuo-ku, Tokyo 104-0045, Japan
  • Local Institution - 40222
    Koto-ku, Tokyo 1358550, Japan
  • Local Institution - 40922
    Fukuoka, 812-8582, Japan
  • Local Institution - 40122
    Isehara City, Kanagawa, 259-1193, Japan
  • Local Institution - 41522
    Kashiwa, 277-8577, Japan
  • Local Institution - 41622
    Nagoya, 460-0001, Japan
  • Local Institution - 41222
    Sendai, 980-8574, Japan
  • Local Institution - 41322
    Tsukuba, 305-8576, Japan
09

References and documents

Publications

  • Dupuis J, Bachy E, Morschhauser F, Cartron G, Fukuhara N, Daguindau N, Casasnovas RO, Snauwaert S, Gressin R, Fox CP, d'Amore FA, Staber PB, Tournilhac O, Bouabdallah K, Thieblemont C, Andre M, Rai S, Ennishi D, Gkasiamis A, Nishio M, Fornecker LM, Delfau-Larue MH, Sako N, Mule S, de Leval L, Gaulard P, Tsukasaki K, Lemonnier F. Oral azacitidine compared with standard therapy in patients with relapsed or refractory follicular helper T-cell lymphoma (ORACLE): an open-label randomised, phase 3 study. Lancet Haematol. 2024 Jun;11(6):e406-e414. doi: 10.1016/S2352-3026(24)00102-9. PubMed 38796193 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2018 to primary completion in Feb 2021, 27 months.

Results were first posted in Jul 2024, 3 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2018
First posted
Oct 12, 2018
StartActual
Nov 6, 2018
Primary completionActual
Feb 10, 2021
CompletionActual
Mar 30, 2026
Results first posted
Jul 8, 2024
Last update
Jun 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03703375
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
Oct 12, 2018
Start date
Nov 6, 2018
Primary completion
Feb 10, 2021
Completion
Mar 30, 2026
Results posted
Jul 8, 2024
Last update
Jun 12, 2026

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Azacitidine

Start the discussion